Literature DB >> 33607074

Paracrine TGF-β1 from breast cancer contributes to chemoresistance in cancer associated fibroblasts via upregulation of the p44/42 MAPK signaling pathway.

Bikash Chandra Jena1, Chandan Kanta Das1, Indranil Banerjee1, Subhayan Das1, Deblina Bharadwaj1, Ranabir Majumder1, Mahitosh Mandal2.   

Abstract

Conventionally, Cancer-associated fibroblasts (CAFs) are considered as an inducer of chemoresistance in cancer cells. However, the underlying mechanism by which carcinomas induce chemoresistance in CAFs through tumor-stroma cross-talk is largely unknown. Henceforth, we uncovered a network of paracrine signals between carcinoma and CAFs that drives chemoresistance in CAFs. Acquired tamoxifen and 5-Fu resistant cell lines MCF-7 and MDA-MB-468 respectively showed higher apoptotic resistance compared to the parental cell. Besides, chemoresistant breast cancer cells showed overexpression of TGF-β1 and have the higher potential to induce CAF phenotype in the normal dermal fibroblasts in a paracrine manner through the TGF-β1 cytokine, compared to their parental cell. Moreover, the chemoresistant cancer cells augmented the EMT markers with a reduction of E-cadherin in the CAFs. Importantly we found out that the TGF- β1 enriched conditioned media from both of the resistant cells triggered chemoresistance in the CAFs by p44/42 MAPK signaling axis. Mechanistically, pharmacological and genetic blockade of TGF-β1 inhibits p44/42 MAPK activation with the subsequent restoration of chemosensitivity in the CAFs. Altogether we ascertained that chemoresistant cancer cells have tremendous potential to modulate the CAFs compared to the parental counterpart. Targeting TGF-β1 and p44/42 MAPK signaling in the future may help to abrogate the chemoresistance in the CAFs.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer-associated fibroblasts; Chemoresistance; TGF-β1; p44/42 MAPK pathway

Year:  2021        PMID: 33607074     DOI: 10.1016/j.bcp.2021.114474

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

Review 1.  Lipid metabolism in tumor microenvironment: novel therapeutic targets.

Authors:  Xingkai Liu; Ping Zhang; Jing Xu; Guoyue Lv; Yan Li
Journal:  Cancer Cell Int       Date:  2022-07-05       Impact factor: 6.429

2.  MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.

Authors:  Renjie Yang; Dong Wang; Shen Han; Yichao Gu; Zhi Li; Lei Deng; Aihong Yin; Yun Gao; Xiangcheng Li; Yue Yu; Xuehao Wang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 10.750

3.  Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.

Authors:  Ruoyao Zou; Qidi Jiang; Tianqiang Jin; Mo Chen; Liangqing Yao; Hongda Ding
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.